Baidu
map

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial

Puszkiel, A; You, BN; Payen, L; Lopez, J; Guitton, J; Rousset, P; Fontaine, J; Peron, J; Maillet, D; Tartas, S; Bonnin, N; Trillet-Lenoir, V; Colomban, O; Augu-Denechere, D; Freyer, G; Tod, M

You, BN (通讯作者)，Univ Claude Bernard Lyon 1, Fac Med Lyon Sud, EA CICLY 3738, Lyon, France.;You, BN (通讯作者)，Ctr Hosp Lyon Sud, Inst Cancerol Hosp Civils Lyon HCL, Med Oncol, CITOHL, 165 Chemin Grand Revoyet, F-69495 Lyon, France.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (5): 413

Abstract

Purpose The objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

Baidu
map
Baidu
map
Baidu
map